

Programme: Saturday 22 June



ALL SESSIONS IN EUROPA HALL UNLESS OTHERWISE INDICATED

07:30-11:50

Foramen Magnum Stenosis in Children with Achondroplasia Working Group

See page 20

MOZART 1/2

10:00-11:50

CONCURRENT SESSIONS

Pre-meeting networking events (*pre-booking required*)

Networking – New Investigators

Organiser: Alex Ireland (*Manchester, UK*)

MOZART 4

How did I get here?

Rachel Duckham (*Melbourne, Australia*)

Heike Hoyer-Kuhn (*Cologne, Germany*)

Round table discussions with senior investigators:

Building your profile and network

Disseminating your work

Funding your science (and yourself!)

Developing your skills

Group discussion

Networking – Allied Health Professionals

Organiser: Nicola Crabtree (*Birmingham, UK*)

MOZART 5

10:00

Introduction and housekeeping

10:05

Management of children with severe osteogenesis imperfecta / Patient experiences seen through 'Stop Motion' animation

Jas Sahota (*Birmingham, UK*) /

Kirandeep Basraka (*Birmingham, UK*)

10:20

New treatment in XLH, case studies and results from a cohorted start to treatment

Ian Tucker (*Bristol, UK*)

10:35

Imaging in metabolic bone disease

Alistair Calder (*London, UK*)

10:50

From conception to the retailer. How to make your specialised equipment commercially available

Jill Massey (*London, UK*)

11:05

Surgery and rehabilitation for children with X-linked hypophosphataemia

Gabriel Mindler (*Vienna, Austria*)

11:20

The patient and parental perspective – XLH

Tenna Toft (*XLH-Patient Association, Denmark*)

11:35

Coffee

11:50

Close

Programme: Saturday 22 June



ALL SESSIONS IN EUROPA HALL UNLESS OTHERWISE INDICATED

12:00-13:00

Sponsored Workshop

13:00-13:30

LUNCH

13:30-14:30

Challenge the Expert

Organisers: Craig B Langman (*Chicago, USA*)
Leanne Ward (*Ottawa, Canada*)

13:30

Case 1: Fibrous dysplasia

Author: Soraya Lopes Sader (*Sao Paulo, Brazil*)

Presenter and discussant:

Alison Boyce (*Bethesda, USA*)

13:50

Case 2: 4-year old boy with terrible leg pain post bone marrow transplant: Infection? Scurvy? Other?

Author: Paivi Miettunen (*Calgary, Canada*)

Presenter and discussant:

Nick Shaw (*Birmingham, UK*)

14:10

Case 3: Bone fragility, abnormal neurology and bleeding disorder – a challenging case

Author: Belinda Crowe (*London, UK*)

Discussant: Craig Munns (*Sydney, Australia*)

14:30-15:30

Workshop: Bone fragility during childhood - beyond osteogenesis imperfecta

Chair: Francis Glorieux (*Montreal, Canada*)

14:30

Infant case

Nick Bishop (*Sheffield, UK*)

14:50

Child case

Jean-Pierre Salles (*Toulouse, France*)

15:10

Adolescent case

Craig Munns (*Sydney, Australia*)

15:30-15:45

Coffee Break

15:45-16:45

Symposium: Two years in review

Chairs: Nicola Crabtree (*Birmingham, UK*)
Antonella Forlino (*Pavia, Italy*)

15:45

Highlights in basic bone research

Matthew Warman (*Boston, USA*)

16:15

Highlights in clinical bone research

Nick Shaw (*Birmingham, UK*)

16:50-17:00

Welcome Address

Chairs: Nick Bishop (*Sheffield, UK*)
Gabriele Häusler (*Vienna, Austria*)

17:15-18:45

Satellite Symposium

19:00-19:45

Welcome Reception

CONGRESS CENTRE AND GARDENS

Programme: Sunday 23 June



ALL SESSIONS IN EUROPA HALL UNLESS OTHERWISE INDICATED

08:00-08:45

Meet the Expert Sessions

Limited availability. Tickets can be picked up from the registration desk on Saturday on a first-come first-served basis

Therapeutic management of hypophosphatemic rickets

Agnès Linglart (*Paris, France*)

MOZART 1

Assessment of neuromuscular function and physical activity

Alex Ireland (*Manchester, UK*)

MOZART 4

What you need to know about bone histomorphometry

Klaus Klaushofer (*Vienna, Austria*)

MOZART 5

09:00-10:30

Symposium: Bone development

Chairs: Suzanne Bechtold-Dalla Pozza (*Munich, Germany*)

Alex Ireland (*Manchester, UK*)

09:00

Biomechanics of fetal movements

Niamh Nowlan (*London, UK*)

09:30

Mechanical loading and bone development - insights from epidemiological studies

Jon Tobias (*Bristol, UK*)

10:00

Spine development

Vicente Gilsanz (*Los Angeles, USA*)

10:30-11:00

Coffee Break &

Moderated ePosters (Screens 1-4)

EPOSTER SCREEN 1

Moderator: Munier Nour (*Saskatoon, Canada*)

P51 Higher dose of burosumab is needed for treatment of children with severe forms of X-linked hypophosphatemia

Volha V Zhukouskaya (*Le Kremlin-Bicêtre, France*)

P127 Burosumab therapy in pediatric patients with X-linked hypophosphatemia improves body composition

Avivit Brener (*Tel Aviv, Israel*)

P75 Active vitamin D analogues and oral phosphate for the treatment of X-linked hypophosphatemia in paediatric patients: A systematic literature review and survey of expert opinion on current needs

Zulf Mughal (*Manchester, United Kingdom*)

P70 Metabolic bone disease of prematurity – comparing neonatal and endocrine approaches using a nationwide survey

Amish Chinoy (*Manchester, United Kingdom*)

EPOSTER SCREEN 2

Moderator: Gali Guterman Ram (*Bethesda, USA*)

P150 Osteogenesis imperfecta: Skeletal outcomes after bisphosphonates discontinuation at final height

Marie-Eve Robinson (*Montreal, Canada*)

P37 Generation of osteogenesis imperfecta type XIV zebrafish models

Laura Leoni (*Pavia, Italy*)

P133 Losartan reduces circulating TGFb and CTX and increases vertebral bone mass in the OIM mouse

Nick Bishop (*Sheffield, United Kingdom*)

P121 An Acvr1[R258G] “conditional on” mouse model of atypical fibrodysplasia ossificans progressiva (FOP) is activin A dependent

Sarah Hatsell (*Tarrytown, United States*)

EPOSTER SCREEN 3

Moderator: Alessandra Cocca (*London, UK*)

P99 Pre and post-natal achondroplasia, retrospective series of 64 consecutive cases with analyze of the diagnostic methods and timing issues

Genevieve Baujat (*Paris, France*)

P221 Speech and hearing impairment and respiratory complications in a large cohort of patients with achondroplasia

Alessandra Cocca (*London, United Kingdom*)

P148 Management of foramen magnum stenosis in patients with achondroplasia: relative merit of clinical and radiological indications for foramen magnum decompression

William Singleton (*Bristol, United Kingdom*)

P15 TA-46 prevents premature synchondrosis and restores foramen magnum size in a mouse model of achondroplasia

Guylene Rignol (*Nice, France*)

EPOSTER SCREEN 4

Moderator: Stephanie Borg (*Sheffield, UK*)

P110 Cost-effectiveness of a vitamin D supplementation programme in pregnant women and children to prevent rickets in the UK

Raja Padidela (*Manchester, United Kingdom*)

P5 Response of bone to mechanical stimulation in the offspring of MAVIDOS study mothers in a single centre; the effect of antenatal vitamin D supplementation

Sujatha Gopal (*Sheffield, United Kingdom*)

Programme: Sunday 23 June



ALL SESSIONS IN EUROPA HALL UNLESS OTHERWISE INDICATED

- P98 The effect of vitamin D on bone health assessed by radiogrammetry: a double-blind placebo-controlled vitamin D supplementation trial in infants
Suma Uday (*Birmingham, United Kingdom*)
- P174 Supplementation of children with type 1 diabetes with milk or pharmacological calcium for improving bone health: A randomized controlled trial
Sonal Palande (*Pune, India*)

11:00-11:30

Charles Slemenda Award Lecture

- Chairs: **Leanne Ward** (*Ottawa, Canada*)
Frank Rauch (*Montreal, Canada*)

11:30-12:00

Oral Communications

- Chairs: **Klaus Klaushofer** (*Vienna, Austria*)
Jon Tobias (*Bristol, UK*)
- 11:30
- OC1 Association between age at puberty and bone accrual up to 25 years-old
Ahmed Elhakeem (*Bristol, United Kingdom*)
- 11:40
- OC2 Adolescent pregnancy and bone density in premenopausal women
Anuradha Khadilkar (*Pune, India*)
- 11:50
- OC3 Osteocyte lacunae characteristics in healthy children
Stéphane Blouin (*Vienna, Austria*)

12:00-13:00

Posters

Odd numbers presented

13:00-14:00

LUNCH

14:00-15:30

Symposium: Vitamin D

- Chairs: **Jeremy Allgrove** (*London, UK*)
Nick Shaw (*Birmingham, UK*)
- 14:00
Nutritional rickets – a socioeconomic problem
Wolfgang Högler (*Linz, Austria*)
- 14:30
Effect of vitamin D on body composition
Hope Weiler (*Montreal, Canada*)
- 15:00
Vitamin D in pregnancy and offspring immunology
Catherine Hawrylowicz (*London, UK*)

15:30-16:30

Oral Communications

- Chairs: **Nathalie Alos** (*Montreal, Canada*)
Zulf Mughal (*Manchester, UK*)
- 15:30
- OC4 Early life vitamin D depletion and mechanical loading determine methylation changes in the RXRA, Runx2 and osterix promoters in mice
Stephanie Borg (*Sheffield, United Kingdom*)
- 15:40
- OC5 Low birthweight is associated with poorer limb muscle mass and grip strength in middle age: findings from the UK Biobank Imaging Enhancement
Elizabeth Curtis (*Southampton, United Kingdom*)
- 15:50
- OC6 Anthropometric characteristics of pediatric patients with hypophosphatasia: data from the Global Hypophosphatasia Patient Registry
Wolfgang Högler (*Linz, Austria*)
- 16:00
- OC7 Comparison of zoledronate and pamidronate in children with skeletal disorders: short term safety experience from a single institution
Laura Tosi (*Washington, United States*)
- 16:10
- OC8 Bisphosphonate improves hip range of motion and pain but not femoral head sphericity. A multicentre, randomized clinical trial of children with Perthes disease
Craig Munns (*Westmead, Australia*)

Programme: Sunday 23 June



ALL SESSIONS IN EUROPA HALL UNLESS OTHERWISE INDICATED

16:20

- OC9 Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial
Leanne Ward (Ontario, Canada)

16:30-17:00

Coffee Break & Moderated ePosters (Screens 1-4)

EPOSTER SCREEN 1

Moderator: Melissa Fiscaletti (Montreal, Canada)

- P77 Long-term efficacy profile of asfotase alfa in the treatment of patients with hypophosphatasia: a pooled analysis
Michael P Whyte (Saint Louis, United States)
- P114 Hypophosphatasia in Japan: ALPL mutation analysis in 98 patients
Toshimi Michigami (Izumi, Japan)
- P62 Tissue non-specific alkaline phosphatase activity and mineralization capacity of bi-allelic mutations from severe perinatal and asymptomatic hypophosphatasia phenotypes: Results from an in-vitro mutagenesis model
Suma Uday (Birmingham, United Kingdom)
- P212 Genetic loss of heparanase does not inhibit osteochondromas in Ext1 and Ext2 double heterozygous hereditary multiple osteochondroma mouse model
Kalyan Nannuru (Tarrytown, United States)

EPOSTER SCREEN 2

Moderator: Jill Simmons (Nashville, USA)

- P46 Vertebral fractures are more prevalent than long bone fractures in boys with glucocorticoid-treated Duchenne Muscular Dystrophy: Results of a prospective observational study
Stefan A Jackowski (Ottawa, Canada)
- P156 Patients with nephropathic cystinosis display lower cortical thickness and grip strength
Susanne Bechtold-Dalla Pozza (Munich, Germany)
- P63 Bone geometry and microarchitecture deficits in children with Alagille Syndrome
Joseph Kindler (Philadelphia, United States)
- P81 Bone health in adolescent females with anorexia nervosa may be preserved by high lean mass
Munier Nour (Saskatoon, Canada)

EPOSTER SCREEN 3

Moderator: Kristen Pan (Bethesda, USA)

- P42 FGF 23 measurements in children with fibrous dysplasia: useful or not?
Zilla Huma (London, United Kingdom)
- P220 New perspectives in diagnosis and management of optic neuropathy in fibrous dysplasia: utility of optical coherence tomography and computed tomography measurements
Kristen Pan (Bethesda, United Kingdom)
- P80 Characterization of pain in patients with fibrous dysplasia
Tiahna Spencer (Bethesda, United States)
- P209 Persistently low trabecular bone mineral density and normal bone strength at the radius over 3 years after simultaneous pancreas kidney transplantation
Ondrej Soucek (Prague, Czech Republic)

EPOSTER SCREEN 4

Moderator: Heike Hoyer-Kuhn (Cologne, Germany)

- P151 The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: A randomized controlled pilot trial
Marie-Eve Robinson (Montreal, Canada)
- P152 An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis
Marie-Eve Robinson (Montreal, Canada)
- P129 A smartphone based survey of frequency and severity of adverse effects following bisphosphonate therapy in a tertiary paediatric centre
James Blackburn (Liverpool, United Kingdom)

17:00-18:30

Satellite Symposium

18:30-18:45

Foramen Magnum Stenosis in children with Achondroplasia Working Group Update

Moira Cheung (London, UK)

Free evening

Programme: Monday 24 June



ALL SESSIONS IN EUROPA HALL UNLESS OTHERWISE INDICATED

08:00-08:45

Meet the Expert Sessions

Limited availability. Tickets can be picked up from the registration desk on Sunday on a first-come first-served basis

Ectopic mineralization

Frank Rutsch (*Münster, Germany*)

MOZART 1

Bone in neuromuscular disorders

Zulf Mughal (*Manchester, UK*)

MOZART 4

Skeletal involvement in chronic kidney diseases

Craig B Langman (*Chicago, USA*)

MOZART 5

09:00-10:30

CONCURRENT SESSIONS

Symposium: Bone cells

Chairs: Meena Balasubramanian (*Sheffield, UK*)
Junya Toguchida (*Kyoto, Japan*)

09:00

Osteoclast disorders

Cristina Sobacchi (*Milan, Italy*)

Endoplasmic reticulum stress in osteoblasts

Antonella Forlino (*Pavia, Italy*)

Clock genes and bone and mineral regulation

Masanobu Kawai (*Osaka, Japan*)

Allied Health Professionals Session

Chairs: Nicola Crabtree (*Birmingham, UK*)

MOZART 4

P181 Walking quality of children with healed Perthes disease

Verity Pacey (*Westmead, Australia*)

P17 Sex and maturation effects on trabecular and cortical microarchitecture in children and young adults

Tandy Aye (*California, United States*)

P93 Assessing the ability of vibration analysis to differentiate wrist and ankle fractures from sprains in children

David Fennimore (*Sheffield, United Kingdom*)

P9 Do lifestyle factors play a role on bone health in boys diagnosed with Autism Spectrum Disorder? Preliminary data from the Promoting bone and gut health in our children (PROUD) study

Rachel L Duckham (*Geelong, Australia*)

P177 Feasibility of a 13-week targeted exercise intervention on tibial bone mineral density in adolescents with Developmental Coordination Disorder

Jocely Tan (*Fremantle, Australia*)

P74 Burosumab can improve pain and quality of life for children with X-linked hypophosphataemia and their families: a London centre's experience

Robyn Gilbey-Cross (*London, United Kingdom*)

P185 High impact exercise to improve musculoskeletal outcomes in Crohn's disease: a feasibility questionnaire

Lewis Steell (*Glasgow, United Kingdom*)

P197 A playful type of intervention for infants with osteogenesis imperfecta

Rebecca Jones (*Sheffield, United Kingdom*)

P79 Novel imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH)

Adalbert Raimann (*Vienna, Austria*)

10:30-11:00

Coffee Break &

Moderated ePosters (Screens 1-4)

EPOSTER SCREEN 1

Moderator: Marie-Eve Robinson (*Montreal, Canada*)

P27 Response to mechanical stimulation of bone in children with osteogenesis imperfecta and the effect of bisphosphonate therapy

Sivagamy Sithambaran (*Sheffield, United Kingdom*)

P199 Diversity of outcomes in randomised trials of interventions for children with osteogenesis imperfecta

Richard McGee (*Westmead, Australia*)

P137 Reversion to pamidronate after switch to zoledronic acid in children with bone disease

Amanda Peacock (*Sheffield, United Kingdom*)

P143 Intermittent bi-daily sub-cutaneous teriparatide infusion in children with hypoparathyroidism: a single-centre experience

Sacha Flammier (*Lyon, France*)

EPOSTER SCREEN 2

Moderator: Ahmed Elhakeem (*Bristol, UK*)

P41 Increased prevalence of fractures in poorly chelated children with beta thalassemia

Sonal Palande (*Pune, India*)

P87 Assessment of bone density by DXA in poorly controlled children with β -Thalassemia: Correction for hepatic iron -overload by manual analysis

Sonal Palande (*Pune, India*)

Programme: Monday 24 June



ALL SESSIONS IN EUROPA HALL UNLESS OTHERWISE INDICATED

P89 Use of DXA and pQCT measurements to screen for fracture risk in 3 to 18 year old poorly chelated thalassaemic children

Sonal Palande (*Pune, India*)

P14 Bone health in children with congenital heart disease

Marta Erlandson (*Saskatoon, Canada*)

EPOSTER SCREEN 3

Moderator: Elizabeth Curtis (*Southampton, UK*)

P16 Higher neonatal bone mineral content and lower IL-6 levels in offspring of overweight/obese women following antenatal exercise: The IMPROVE randomized controlled trial (RCT)

Sumudu Nimali Seneviratne (*Colombo, Sri Lanka*)

P163 Prenatal oligohydramnios is associated with hip shape in adolescent males

Alex Ireland (*Manchester, United Kingdom*)

P154 Self-reported sedentary time is negatively associated with microarchitecture of the tibia

Rebecca Moon (*Southampton, United Kingdom*)

P9 Do lifestyle factors play a role on bone health in boys diagnosed with Autism Spectrum Disorder? Preliminary data from the Promoting bone and gut health in our children (PROUD) study

Rachel L Duckham (*Geelong, Australia*)

EPOSTER SCREEN 4

Moderator: Suzanne Bechtold-Dalla Pozza (*Munich, Germany*)

P17 Sex and maturation effects on trabecular and cortical microarchitecture in children and young adults

Tandy Aye (*California, United States*)

P83 Could digital X-ray radiogrammetry be an alternative for dual energy X-ray absorptiometry

Jos Draaisma (*Nijmegen, Netherlands*)

P11 Reference values of cortical thickness, bone width, and Bone Health Index in metacarpals of children from age 0 y, as determined with an extension of the fully automated BoneXpert bone age method

Hans Henrik Thodberg (*Hørsholm, Denmark*)

P94 Characteristics of ultradistal radius bone density during childhood: Results from the Bone Mineral Density in Childhood Study

Joseph Kindler (*Philadelphia, United States*)

11:00-12:00

Oral Communications

Chairs: Valérie Cormier-Daire (*Paris, France*)
Agnès Lingart (*Paris, France*)

11:00

OC10 Next-generation antibody-guided enzyme replacement therapy for lysosomal storage diseases

Katherine Cygnar (*Tarrytown, United States*)

11:10

OC11 Targeting adeno-associated viral vectors to fractures and the skeleton

Lucinda Lee (*Westmead, Australia*)

11:20

OC12 Combination treatment of a novel activin receptor IIB ligand trap and zoledronate improves muscle and bone properties in a mouse model of osteogenesis imperfecta

Iris Boraschi-Diaz (*Montreal, Canada*)

11:30

OC13 Analysis of osteogenesis imperfecta in pathology and the effects of 4-phenylbutyric acid using patient-derived fibroblasts and induced pluripotent stem cells

Shinji Takeyar (*Osaka, Japan*)

11:40

OC14 Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia

Leanne Ward (*Ontario, Canada*)

11:50

OC15 Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemia

Wolfgang Högl (*Linz, Austria*)

12:00-13:00

Posters

Even numbers presented

13:00-14:00

LUNCH

Programme: Monday 24 June



ALL SESSIONS IN EUROPA HALL UNLESS OTHERWISE INDICATED

14:00-15:30

Symposium: Surgical aspects in rare bone disorders

Chairs: Frank Rauch (*Montreal, Canada*)
Oliver Semler (*Cologne, Germany*)

14:00

Orthopedic management of osteogenesis imperfecta in the bisphosphonate era

François Fassier (*Montreal, Canada*)

14:30

Craniosynostoses in rare skeletal disorders

Federico Di Rocco (*Lyon, France*)

15:00

Orthopedic needs in X-linked hypophosphatemic rickets

Rudolf Ganger (*Vienna, Austria*)

15:30-16:00

Coffee Break & Moderated ePosters (Screens 1-4)

EPOSTER SCREEN 1

Moderator: Rachel Harrison (*Sheffield, United Kingdom*)

P109 Fracture prevalence in children 0-19 years-old in Mexico: A 10-year cross-sectional analysis
Patricia Clark (*Mexico City, Mexico*)

P22 Tibia microarchitecture in children with recent fractures
Rebecca Moon (*Southampton, United Kingdom*)

P93 Assessing the ability of vibration analysis to differentiate wrist and ankle fractures from sprains in children
David Fennimore (*Sheffield, United Kingdom*)

P25 Short term mechanical stimulation using whole body vibration identifies differences in bone response between prepubertal boys with and without prior fracture
Rachel Harrison (*Sheffield, United Kingdom*)

EPOSTER SCREEN 2

Moderator: Sonal Palande (*Pune, India*)

P44 Bone mass and vertebral fractures in South African (SA) children on prolonged oral glucocorticoids (GCs) for chronic non-malignant illnesses
Kebashni Thandrayen (*Johannesburg, South Africa*)

P18 Bone mass and fracture prevalence in Childhood Brain Cancer Survivors (CBCS) 2 or 5 years after off therapy
Natascia di Iorgi (*Genova, Italy*)

P23 What happens to the skeleton at the time of diagnosis of paediatric cancer?

Artemis Doulgeraki (*Athens, Greece*)

P164 Musculoskeletal deficits persist up to two years despite anti-TNF-alpha antibody therapy in children with Crohn's disease: Results of a prospective, observational inception cohort study

Stefan A Jackowski (*Ottawa, Canada*)

EPOSTER SCREEN 3

Moderator: Oliver Semler (*Cologne, Germany*)

P107 Sex differences in the longitudinal associations between body composition and bone stiffness index in European children and adolescents
Lan Cheng (*Bremen, Germany*)

P155 Gender specific paediatric reference data for muscle function parameters assessed using jumping mechanography
Sonal Palande (*Pune, India*)

P159 Determinants of muscle function in 6 to 11 year old rural Indian children
Sonal Palande (*Pune, India*)

P181 Walking quality of children with healed Perthes disease
Verity Pacey (*Westmead, Australia*)

EPOSTER SCREEN 4

Moderator: Carla Caffarelli (*Siena, Italy*)

P120 Mutational and phenotypic spectra in 137 Russian patients with inherited forms of rickets
Kristina Kulikova (*Moscow, Russian Federation*)

P125 SCN8a mutations and osteoporosis. Is osteocyte dysfunction the cause or the consequence?
Gillian O'Donnell (*Dublin, Ireland*)

P113 Next-generation sequence and biomarker levels in the patients with early-onset chronic non-bacterial osteomyelitis from North Caucasian region of Russia
Mikhail Kostik (*St Petersburg, Russian Federation*)

P13 Clinical implications of modeling the maturational spurt
Melanie Boeyer (*Missouri, United States*)

Programme: Monday 24 June



ALL SESSIONS IN EUROPA HALL UNLESS OTHERWISE INDICATED

16:00-17:15

Oral Communications

Chairs: Alison Boyce (*Bethesda, USA*)

Craig B Langman (*Chicago, USA*)

16:00

- OC16 A natural history study of generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemic rickets (ARHR2) due to ENPP1 or ABCC6 deficiency: Interim analysis

Yvonne Nitschke (*Münster, Germany*)

16:10

- OC17 Growth curves for children with X-linked hypophosphatemia

Meng Mao (*Novato, United States*)

16:20

- OC18 Developing a human-mouse hybrid model of osteogenesis imperfecta for investigating new therapies for children

Fawaz Arshad (*Sheffield, United Kingdom*)

16:30

- OC19 Altered 3 hydroxylation complex in bone homeostasis

Francesca Tonelli (*Pavia, Italy*)

16:40

- OC20 Identifying the role of NBAS in bone fragility using zebrafish and exploring therapeutic targets to reverse NBAS activity

Meena Balasubramanian (*Sheffield, United Kingdom*)

16:50

- OC21 New mouse model with IFITM5 S42L for atypical type VI osteogenesis imperfecta

Gali Guterman Ram (*Bethesda, United States*)

16:60

- OC22 Bone tissue phenotyping reveals increased matrix mineralization, elevated osteocyte lacunar density and altered vascularity in a new OI mouse model carrying a leucine substitution for the BRIL p.Serine42 residue

Ghazal Hedjazi (*Vienna, Austria*)

17:30-19:00

Satellite Symposium

20:00-23:00

Conference Dinner

STIEGLKELLER RESTAURANT

Programme: Tuesday 25 June



ALL SESSIONS IN EUROPA HALL UNLESS OTHERWISE INDICATED

08:00-08:45

Meet the Expert Sessions

Limited availability. Tickets can be picked up from the registration desk on Monday on a first-come first-served basis

Genetic testing for recurrent fractures – when and what?

Outi Mäkitie (*Helsinki, Finland*)

MOZART 1

Management of fibrous dysplasia

Alison Boyce (*Bethesda, USA*)

MOZART 4

Vibration treatment

Oliver Semler (*Cologne, Germany*)

MOZART 5

09:00-10:00

Symposium: An update on skeletal dysplasias

Chairs: **Laurence Legeai-Mallet** (*Paris, France*)
Coen Netelenbos (*Amsterdam, Netherlands*)

09:00

Diagnosis of bone dysplasia

Valérie Cormier-Daire (*Paris, France*)

09:30

Achondroplasia

Noriyuki Namba (*Osaka, Japan*)

10:00-11:00

Oral Communications

Chairs: **Moira Cheung** (*London, UK*)
Noriyuki Namba (*Osaka, Japan*)

10:00

OC23 Effects of the FGF2 aptamer on growth plate cartilage development of achondroplasia patient-specific iPS cells in a xenograft model
Takeshi Kimura (*Osaka, Japan*)

10:10

OC24 TA-46, a recombinant soluble FGFR3 receptor for the treatment of achondroplasia, is safe and well-tolerated in healthy volunteers
Samuel Collins (*Basel, Switzerland*)

10:20

OC25 TransCon CNP: Potential for a once weekly novel therapy in children with achondroplasia
David Karpf (*Palo Alto, United States*)

10:30

OC26 [18F] NaF PET/CT the first tool to diagnose chronic activity in FOP at all ages?
Coen Netelenbos (*Amsterdam, Netherlands*)

10:40

OC27 Palovarotene inhibits the development of new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP)

Richard Keen (*Stanmore, United Kingdom*)

10:50

LB1 Genetic inactivation of osteocalcin in Col1a1Jrt/+ mice, a model of dominant osteogenesis imperfecta, restores glucose metabolism to wild-type levels

Josephine Tauer (*Montreal, Canada*)

10:55

LB2 Lumbar spine quantitative computed tomography (QCT) is a better predictor of vertebral fracture in boys with Duchenne muscular dystrophy (DMD) than either DXA or peripheral QCT

Nicola Crabtree (*Birmingham, United Kingdom*)

11:00-11:15

Coffee Break

11:15-11:30

Presentation of awards

Chairs: **Frank Rauch** (*Montreal, Canada*)
Leanne Ward (*Ottawa, Canada*)

11:30-12:30

Symposium: Approaches to treating low bone mass disorders

Chairs: **Outi Mäkitie** (*Helsinki, Finland*)
Peter Simm (*Sydney, Australia*)

11:30

TGFbeta inhibition in osteogenesis imperfecta
Ingo Grafe (*Houston, USA*)

12:00

Antiresorptive treatment

Leanne Ward (*Ottawa, Canada*)

12:30

Close and Final Remarks

Chair: **Nick Bishop** (*Sheffield, UK*)

12:35

Buses to Airport